252 related articles for article (PubMed ID: 30614795)
1. The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer.
Li H; Wang H; Deng K; Han W; Hong B; Lin W
Cancer Biomark; 2019; 24(1):51-59. PubMed ID: 30614795
[TBL] [Abstract][Full Text] [Related]
2. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
Faber AC; Farago AF; Costa C; Dastur A; Gomez-Caraballo M; Robbins R; Wagner BL; Rideout WM; Jakubik CT; Ham J; Edelman EJ; Ebi H; Yeo AT; Hata AN; Song Y; Patel NU; March RJ; Tam AT; Milano RJ; Boisvert JL; Hicks MA; Elmiligy S; Malstrom SE; Rivera MN; Harada H; Windle BE; Ramaswamy S; Benes CH; Jacks T; Engelman JA
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1288-96. PubMed ID: 25737542
[TBL] [Abstract][Full Text] [Related]
3. Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines.
Tahir SK; Wass J; Joseph MK; Devanarayan V; Hessler P; Zhang H; Elmore SW; Kroeger PE; Tse C; Rosenberg SH; Anderson MG
Mol Cancer Ther; 2010 Mar; 9(3):545-57. PubMed ID: 20179162
[TBL] [Abstract][Full Text] [Related]
4. Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer.
Nakajima W; Sharma K; Hicks MA; Le N; Brown R; Krystal GW; Harada H
Cancer Biol Ther; 2016; 17(1):27-35. PubMed ID: 26575826
[TBL] [Abstract][Full Text] [Related]
5. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
[TBL] [Abstract][Full Text] [Related]
6. Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression.
Lochmann TL; Floros KV; Naseri M; Powell KM; Cook W; March RJ; Stein GT; Greninger P; Maves YK; Saunders LR; Dylla SJ; Costa C; Boikos SA; Leverson JD; Souers AJ; Krystal GW; Harada H; Benes CH; Faber AC
Clin Cancer Res; 2018 Jan; 24(2):360-369. PubMed ID: 29118061
[No Abstract] [Full Text] [Related]
7. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
8. ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer.
Kim EY; Jung JY; Kim A; Chang YS; Kim SK
Neoplasia; 2017 Apr; 19(4):354-363. PubMed ID: 28319809
[TBL] [Abstract][Full Text] [Related]
9. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.
Hann CL; Daniel VC; Sugar EA; Dobromilskaya I; Murphy SC; Cope L; Lin X; Hierman JS; Wilburn DL; Watkins DN; Rudin CM
Cancer Res; 2008 Apr; 68(7):2321-8. PubMed ID: 18381439
[TBL] [Abstract][Full Text] [Related]
11. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
[TBL] [Abstract][Full Text] [Related]
12. Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263.
Greenberg EF; McColl KS; Zhong F; Wildey G; Dowlati A; Distelhorst CW
Cell Death Dis; 2015 Dec; 6(12):e2034. PubMed ID: 26720343
[TBL] [Abstract][Full Text] [Related]
13. EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2/BCL-X
Inoue-Yamauchi A; Oda H
Biochem Biophys Res Commun; 2020 Jun; 526(3):612-617. PubMed ID: 32247610
[TBL] [Abstract][Full Text] [Related]
14. Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors.
Lam LT; Lin X; Faivre EJ; Yang Z; Huang X; Wilcox DM; Bellin RJ; Jin S; Tahir SK; Mitten M; Magoc T; Bhathena A; Kati WM; Albert DH; Shen Y; Uziel T
Mol Cancer Ther; 2017 Aug; 16(8):1511-1520. PubMed ID: 28468776
[TBL] [Abstract][Full Text] [Related]
15. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
Tanos R; Karmali D; Nalluri S; Goldsmith KC
BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
[TBL] [Abstract][Full Text] [Related]
16. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y
Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063
[TBL] [Abstract][Full Text] [Related]
17. Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer.
Loriot Y; Mordant P; Dugue D; Geneste O; Gombos A; Opolon P; Guegan J; Perfettini JL; Pierre A; Berthier LK; Kroemer G; Soria JC; Depil S; Deutsch E
Cell Death Dis; 2014 Sep; 5(9):e1423. PubMed ID: 25232677
[TBL] [Abstract][Full Text] [Related]
18. Intracellular levels of reactive oxygen species correlate with ABT-263 sensitivity in non-small-cell lung cancer cells.
Ohgino K; Terai H; Yasuda H; Nukaga S; Hamamoto J; Tani T; Kuroda A; Arai D; Ishioka K; Masuzawa K; Ikemura S; Kawada I; Naoki K; Fukunaga K; Soejima K
Cancer Sci; 2020 Oct; 111(10):3793-3801. PubMed ID: 32687646
[TBL] [Abstract][Full Text] [Related]
19. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
[TBL] [Abstract][Full Text] [Related]
20. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.
Wang Y; Wang Y; Fan X; Song J; Wu H; Han J; Lu L; Weng X; Nie G
Biochem Biophys Res Commun; 2018 Sep; 503(3):1214-1220. PubMed ID: 30017199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
